MKC
53
2
UNP
40
2
PNW
57
4
STT
64
5
AKAM
53
5
ROK
48
2
EXPE
88
2
MNST
52
6
BEN
40
3
NWS
75
6
GPC
35
6
PCG
66
5
AMZN
63
5
LNC
29
4
SLG
38
3
WFC
60
2
SE
60
3
ZTS
40
2
JBHT
48
2
PNR
60
3
MKC
53
2
UNP
40
2
PNW
57
4
STT
64
5
AKAM
53
5
ROK
48
2
EXPE
88
2
MNST
52
6
BEN
40
3
NWS
75
6
GPC
35
6
PCG
66
5
AMZN
63
5
LNC
29
4
SLG
38
3
WFC
60
2
SE
60
3
ZTS
40
2
JBHT
48
2
PNR
60
3
Financhill
Back

Aurinia Pharmaceuticals 10K Form

Buy
58

AUPH
Aurinia Pharmaceuticals

Last Price:
$8.98
Seasonality Move:
22.59%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02 10Q AUPH/Aurinia Pharmaceuticals Quarterly
2023-11-02 10Q AUPH/Aurinia Pharmaceuticals Quarterly
2023-08-03 10Q AUPH/Aurinia Pharmaceuticals Quarterly
2023-05-04 10Q AUPH/Aurinia Pharmaceuticals Quarterly
2022-11-03 10Q AUPH/Aurinia Pharmaceuticals Quarterly
2022-08-04 10Q AUPH/Aurinia Pharmaceuticals Quarterly

Receive AUPH News And Ratings

See the #1 stock for the next 7 days that we like better than AUPH

AUPH Financial Statistics

Sales & Book Value

Annual Sales: $175.5M
Cash Flow: $16.9M
Price / Cash Flow: 45.81
Annual Sales: $2.71
Price / Book: 3.31

Profitability

EPS (TTM): -0.14000
Net Income (TTM): $-22.6M
Gross Margin: $161.4M
Return on Equity: -5.99%
Return on Assets: -4.19%

Aurinia Pharmaceuticals Earnings Forecast

Key Aurinia Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 26 years for AUPH is 91.94%.
  • The Selling, General & Administrative Expenses for AUPH have been equal to 111.12% of Gross Profit Margin.
  • The Research & Development expenses have been 28.28% of Revenue.
  • The Interest Expense is -3.56% of Operating Income.
  • The Net Earning history of AUPH is -44.45% of Total Revenues.
  • Per Share Earnings over the last 26 years have been positive in 14 years.

Aurinia Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AUPH
CUSIP: 05156V
Website: auriniapharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.6
Quick Ratio: 4.9

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 15.62

AUPH Technical Analysis vs Fundamental Analysis

Buy
58
Aurinia Pharmaceuticals (AUPH) is a Buy

Is Aurinia Pharmaceuticals a Buy or a Sell?